MARKET WIREYahoo! Finance Canada • 21h ago
Azitra, Inc. (AZTR) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering Azitra Inc (AZTR) market action, institutional positioning, and fundamental catalysts.
Why AZTR Stock surged +8.72% Today — RQD Quant Desk Flash
$0.84 +8.72% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.85
Azitra Inc (AZTR) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $4.7M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on AZTR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is AZTR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Azitra Inc (NYSE: AZTR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $0.84 (+8.72% 1D, market cap $4.7M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, AZTR ranks #704 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does AZTR compare to APUS and TRAW in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AZTR carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, APUS (Apimeds Pharmaceuticals US Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -6.2%, cap $4.6M) and TRAW (Traws Pharma Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $4.5M). Among the 5-stock peer group, AZTR leads on earnings multiple (N/A) while APUS leads on capital efficiency (-6.2% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for AZTR?
▼
Per AZTR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001701478), Azitra Inc generated $30.7M in revenue (+409322.2% YoY), -$11.0M in net income, and -$11.2M in free cash flow against $5.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.85 (+1.38%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-10.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AZTR)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (33/100 Composite)
🔍 WHY AZTR SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (30% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (30% of score)
FRED Regime × Technicals: 7% of 52W Range • RSI-14 at 40.8 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$0.72+0% Next Q
25
Q2 (-2Q)Grade E$0.72+55.6% Next Q
28
Q3 (-1Q)Grade E$1.12-25% Next Q
30
CurrentGrade E$0.84-8.9% Hist 90D α
33
Trajectory: E (25) → E (33)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a AZTR Turnaround Squeeze
While AZTR currently carries a cautious 33/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.36) and Max Pain ($0.88) forces dealer call-delta covering toward $5.59.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $AZTR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AZTR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why AZTR Stock surged +8.72% Today — RQD Quant Desk Flash
Azitra Inc (AZTR) surged +8.72% to $0.84, trading at 7% of its 52-week range ($0.52 – $5.32). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 7% of its 52-week range ($0.52 – $5.32) with RSI-14 at 40.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.84 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live AZTR Headlines & Catalysts
MARKET WIRESTL.News • 1d ago
Azitra (AZTR) Announces 1-for-10 Reverse Stock SplitSTL.News report covering Azitra Inc (AZTR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREPR Newswire • 1d ago
Azitra, Inc. Announces Reverse Stock SplitPR Newswire report covering Azitra Inc (AZTR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Globe and Mail • 1d ago
Azitra Announces Reverse Stock Split and Share ConsolidationThe Globe and Mail report covering Azitra Inc (AZTR) market action, institutional positioning, and fundamental catalysts.
CATALYSTTimothy Sykes • 1d ago
AZTR Stock Jumps As Azitra Confirms 1-For-10 Reverse SplitTimothy Sykes report covering Azitra Inc (AZTR) market action, institutional positioning, and fundamental catalysts.
RISK WATCHStock Titan • 1d ago
One dose cut the appearance of wrinkles by about 50% in human skin samples after 48 hoursStock Titan report covering Azitra Inc (AZTR) market action, institutional positioning, and fundamental catalysts.
CATALYSTStocksToTrade • 1d ago
AZTR Stock Jumps As Azitra Enacts 1-for-10 Reverse SplitStocksToTrade report covering Azitra Inc (AZTR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
About 85,000 U.S. patients get either of two cancer drugs each year. Azitra's rash trial adds those with related rashes.Stock Titan report covering Azitra Inc (AZTR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 1d ago
AZTR: Update on Rash, Fine Lines & ElasticityBy John Vandermosten, CFA NYSE: AZTR READ THE FULL AZTR RESEARCH REPORT Over the last month, Azitra, Inc. (NYSE: AZTR) has updated investors on its two leading programs and announced a reverse stock split. The ATR-04 Pha
MARKET WIREYahoo • 5d ago
Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial to Include Patients with Rashes due to KRAS and MEK InhibitorsAzitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced amendments to its ongoing P
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AZTR)
- ✓Walkthrough of AZTR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
AZTR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -67.19%📐 HORIZONTAL RANGE
2026-11-03O $0.76H $0.84L $0.76C $0.84VOL 787.9K
RES: $2.17SUP: $0.36SMA50: $1.36SMA200: $1.81
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
AZTR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +409322.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on AZTR today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for AZTR. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AZTR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AZTR)
Health Care Rank #704 of 1015
⚔️ APUS vs AZTR Full Matrix →
1. Head-to-Head Health Care Peer Comparison (AZTR vs. APUS, TRAW, XBIO, CANF)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Azitra Inc (AZTR) ranks #704 by composite RQD confidence (33/100, grade E) and #950 by equity capitalization ($4.7M). Within this direct 5-issuer industry benchmark cohort, AZTR leads on earnings valuation at N/A trailing P/E, while APUS leads on capital efficiency and profitability with -6.2% ROIC and — gross margin. APUS currently holds the highest overall quantitative score in the immediate peer group at 37/100 (D-) compared with AZTR at 33/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AZTR
ACTIVE
Azitra Inc | E | 33/100 | — | — | -35.0% | +8.72% | $4.7M | Benchmark Subject |
| APUS Apimeds Pharmaceuticals US Inc. | D- | 37/100 | — | — | -6.2% | -3.99% | $4.6M | /apus-vs-aztr → |
| TRAW Traws Pharma Inc. | E | 31/100 | — | — | -35.0% | +1.45% | $4.5M | /traw-vs-aztr → |
| XBIO Xenetic Biosciences Inc. | E | 32/100 | — | — | -30.3% | +0.49% | $4.8M | /xbio-vs-aztr → |
| CANF Can-Fite Biopharma Ltd each representing two (2) | E | 25/100 | — | — | -35.0% | +0.62% | $4.9M | /canf-vs-aztr → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001701478 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Azitra Inc (AZTR) reported GAAP revenue of $30.7M (+409322.2% vs. FY2024 revenue of $7.5K , and +4376.2% cumulative change since FY2023) , GAAP net income of -$11.0M, operating cash flow of -$11.2M, and free cash flow of -$11.2M (-10.4% YoY). On the balance sheet, AZTR closed FY2025 with $5.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $30.7M | -$11.0M | -$11.2M | -$11.2M | $5.0M | — |
| FY2024 (FY) | 2024-12-31 | $7.5K | -$9.0M | -$10.2M | -$10.2M | $7.4M | — |
| FY2023 (FY) | 2023-12-31 | $686.0K | -$11.3M | -$7.4M | -$7.4M | — | — |
3. AZTR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs AZTR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Azitra Inc (NYSE: AZTR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $0.84 (+8.72% 1D, market cap $4.7M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, AZTR ranks #704 in composite RQD confidence.
How does AZTR compare to APUS and TRAW in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AZTR carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, APUS (Apimeds Pharmaceuticals US Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -6.2%, cap $4.6M) and TRAW (Traws Pharma Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $4.5M). Among the 5-stock peer group, AZTR leads on earnings multiple (N/A) while APUS leads on capital efficiency (-6.2% ROIC).
What are the biggest fundamental strengths and SEC risk factors for AZTR?
Per AZTR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001701478), Azitra Inc generated $30.7M in revenue (+409322.2% YoY), -$11.0M in net income, and -$11.2M in free cash flow against $5.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is AZTR trading relative to its 50-day, 200-day, and 52-week technical levels?
AZTR last traded at $0.84 (+8.72% on volume of 523,091 shares), positioning the stock -38.24% below its 50-day simple moving average ($1.36) and -53.59% below its 200-day simple moving average ($1.81). Across its 52-week range of $0.52 to $5.32, AZTR sits at the 6.7% percentile with a 14-day RSI of 40.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.94).
ROARABLE RATING BRIEF • RQD 33/100 (E)
✓ SEC XBRL & RQD VERIFIED
AZTR — Azitra Inc: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Azitra Inc (AZTR) earns a live Roarable RQD composite score of 33/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.84 (+8.72% 1D, market capitalization $4.7M).
- Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Azitra Inc (AZTR) is a NYSE-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry..0B. Customers, products, and revenue model are — reported revenue is — for FY 2025 and FY 2024 and $0.7M for FY 2023.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Azitra Inc (AZTR) reported $30.7M in annual revenue (up from $7.5K in FY2024, +409322.2% YoY) and -$11.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($686.0K revenue, -$11.3M net income) through FY2025, AZTR scaled operating cash flow to -$11.2M and free cash flow to -$11.2M, backed by $5.0M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 33/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.52 – $5.32 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Supply_chain is NONE and butterfly_links is empty, so upstream and downstream dependencies are — Sector correlations beyond the Health Care classification are — For a prospective investor, the practical watch item is the reverse split: per the news feed, a 1-for-10 consolidation is being announced, which changes per-share metrics without changing underlying economics, and any resulting share-price dynamics are not resolved by the source data.
- Key Question #1: Can AZTR sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $30.7M and free cash flow of -$11.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is AZTR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
AZTR Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Azitra Inc (AZTR) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo! Finance Canada • 21h ago
Azitra, Inc. (AZTR) Stock Price, News, Quote & History Yahoo! Finance Canada report covering Azitra Inc (AZTR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE STL.News • 1d ago
Azitra (AZTR) Announces 1-for-10 Reverse Stock Split STL.News report covering Azitra Inc (AZTR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE PR Newswire • 1d ago
Azitra, Inc. Announces Reverse Stock Split PR Newswire report covering Azitra Inc (AZTR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Globe and Mail • 1d ago
Azitra Announces Reverse Stock Split and Share Consolidation The Globe and Mail report covering Azitra Inc (AZTR) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Timothy Sykes • 1d ago
AZTR Stock Jumps As Azitra Confirms 1-For-10 Reverse Split Timothy Sykes report covering Azitra Inc (AZTR) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Stock Titan • 1d ago
One dose cut the appearance of wrinkles by about 50% in human skin samples after 48 hours Stock Titan report covering Azitra Inc (AZTR) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST StocksToTrade • 1d ago
AZTR Stock Jumps As Azitra Enacts 1-for-10 Reverse Split StocksToTrade report covering Azitra Inc (AZTR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
About 85,000 U.S. patients get either of two cancer drugs each year. Azitra's rash trial adds those with related rashes. Stock Titan report covering Azitra Inc (AZTR) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
AZTR Bull vs. Bear Conversation Board — What's Your Call at $0.84?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AZTR 🐻 33% BEARISH CONVICTION
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH
🎯 Target: $0.95 (+23.4%)
📌 Pinned Debate Reported cash of $2.1M and a 2.5 Altman Z-Score point to a balance sheet that is not in immediate distress by that measure.
The street is overcomplicating Azitra Inc (AZTR). Reported cash of $2.1M and a 2.5 Altman Z-Score point to a balance sheet that is not in immediate distress by that measure.. With an RQD score of 33/100 (E) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $0.83.
EarningsSniper 🐂 BULL
@ShortSeller_Dan Shorting a 3/20 institutional whale-flow stock at $0.77 is dangerous when funds are rotating into Health Care.
SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH
🎯 Target: $0.59 (-23.4%)
Spot @ $0.77 Negative ROIC of -35%, zero FCF yield, and a Piotroski F-Score of 1/9 indicate ongoing cash burn with weak financial-health signals.
Sitting on the sidelines or leaning short AZTR above $0.77. Negative ROIC of -35%, zero FCF yield, and a Piotroski F-Score of 1/9 indicate ongoing cash burn with weak financial-health signals.. Until Fundamental Cash Engine (5/20) and FCF yield (0.0%) inflect higher, upside is capped near $5.32.